Seeking Alpha

An appeals court has affirmed its favorable ruling for Eli Lilly (LLY +2.6%) in its patent case...

An appeals court has affirmed its favorable ruling for Eli Lilly (LLY +2.6%) in its patent case against Teva (TEVA +0.3%), asserting the claims of LLY's Alimta compound patent are not invalid. Furthermore, the court said it "considered each of Teva’s remaining arguments and find them unpersuasive." The compound patent provides protection for the drug in the U.S. through January of 2017.
Comments (1)
  • doc47
    , contributor
    Comments (1122) | Send Message
     
    If you don't use covered calls to protect yourself at least part way with this stock, you should get out ASAP.
    25 Aug 2012, 07:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector